PROTHENA CORP PUBLIC LTD CO
PRTADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PRTA Earnings Report
EPS Est: $-0.39 | FQ end 2026-06
How PRTA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NEOD001 | Phase 2 | Primary Amyloidosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PROTHENA CORP PUBLIC LTD CO's drug pipeline?→
CatalystAlert tracks 1 drug candidate in PROTHENA CORP PUBLIC LTD CO's (PRTA) pipeline across Phase 2. Its lead program is NEOD001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PROTHENA CORP PUBLIC LTD CO's next FDA catalyst?→
PROTHENA CORP PUBLIC LTD CO's (PRTA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRTA biotech catalysts?→
Add PRTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PROTHENA CORP PUBLIC LTD CO's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.